Stereotaxis began as a research project--developing a magnetic surgical guidance system--that serendipitously became a company without much regard for commercial prospects. The original design was ahead of the technology curve, but innovations in magnetic and imaging systems fortuitously enabled Stereotaxis to turn this concept into a product.
The company's system, however, was and still remains far ahead of the necessary adjunctive drugs and devices necessary to become a viable therapeutic tool in neurology, the area Stereotaxis first sought to pursue.
Looking for applications in other specialties for what it believes is a platform technology, Stereotaxis shifted its focus to cardiology. The company launched a system that has been well-received in the small but growing area of electrophysiology.
Most recently, Stereotaxis has begun to focus on what could be its most significant opportunity: interventional cardiology. Here, too, the company appears to be the beneficiary of good timing: in the era of drug-eluting stents, interventionalists are likely to treat more difficult patients, the cases that could benefit most from Stereotaxis' advanced guidance system.
The company's system, however, was and still remains far ahead of the adjunctive drugs and devices necessary to become a viable therapeutic tool in neurology, the area Stereotaxis first sought to pursue.
By Stephen Levin
For medical device companies, sometimes taking the road less
traveled in developing new technology can lead to significant
opportunities in new or under-served product markets. But in many
cases, there's a reason why that technological road is less
traveled: there's no clearly defined, unmet clinical need for a
product
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.
Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.
After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.
